Uveitis bei juveniler idiopathischer Arthritis – leitliniengerechte Diagnostik und Therapie anhand von Kasuistiken

Zusammenfassung

Zielsetzung Darstellung der aktuellen deutschsprachigen interdisziplinären Leitlinie zur Diagnostik und Therapie der JIA-assoziierten Uveitis (JIA: juvenile idiopathische Arthritis) anhand von Kasuistiken.

Material und Methoden Leitlinie der Deutschen Ophthalmologischen Gesellschaft, der Gesellschaft für Kinder- und Jugendrheumatologie, der Deutschen Gesellschaft für Rheumatologie, des Berufsverbandes der Augenärzte Deutschlands unter Beteiligung von Patientenvertretern. Die unlängst publizierte Primärliteratur wurde kritisch bewertet hinsichtlich Evidenz und Empfehlungen; methodisch wurden Konsensfindung mittels Delphi-Runden und eine externe Begutachtung einbezogen. Die Ergebnisse werden anhand von typischen Fallbeispielen erläutert.

Ergebnisse Bei JIA-Erstdiagnose sollten regelmäßige augenärztliche Kontrollen erfolgen mit dem Ziel, dass die Uveitis vor Manifestation irreversibler Folgeschäden diagnostiziert wird. Entsprechend dem individuellen Schweregrad der Uveitis kann eine qualitativ hochwertige Versorgung der Patienten erzielt werden. Zur antientzündlichen Therapie finden aktuell Kortikosteroide, konventionell synthetische (cs) und biologische (b) und andere Disease-modifying anti-rheumatic Drugs (DMARDs) Verwendung.

Schlussfolgerungen Frühzeitige Diagnose und aktuelle leitliniengerechte Therapie können die Langzeitprognose der JIA-assoziierten Uveitis wesentlich verbessern.

Schlüsselwörter

Diagnostik - juvenile idiopathische Arthritis - Therapie - Uveitis

Publication History

Received: 03 November 2021

Accepted: 13 December 2021

Article published online:
23 March 2022

• References/Literatur

• 1 Heiligenhaus A, Niewerth M, Ganser G. et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007; 46: 1015-1019
• 2 Kotaniemi K, Kautiainen H, Karma A. et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis. A prospective study. Ophthalmology 2001; 108: 2071-2075
• 3 Walscheid K, Glandorf K, Rothaus K. et al. Enthesitis-related arthritis: prevalence and complications of associated uveitis in children and adolescents from a population-based nationwide study in Germany. J Rheumatol 2021; 48: 262-269
• 4 Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516
• 5 De Boer J, Steijaert A, van den Bor R. et al. Development of macular edema and impact and visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm 2015; 23: 67-73
• 6 Böhm MR, Tappeiner C, Breitbach MA. et al. Ocular hypotony in patients with juvenile idiopathic arthritis-associated uveitis. Am J Ophthalmol 2017; 173: 45-55
• 7 Thorne JE, Woreta FA, Dunn JP. et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117: 1436-1441
• 8 Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm 2013; 21: 478-485
• 9 De Boer J, Wulffraat N, Rothova A. Visual loss in uveitis of childhood. Br J Ophthalmol 2003; 87: 879-884
• 10 Tappeiner C, Klotsche J, Schenck S. et al. Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis: data from a cross-sectional analysis of a prospective nationwide study. Clin Exp Rheumatol 2015; 33: 936-944
• 11 Heiligenhaus A, Minden K, Tappeiner C. et al. Update of the evidence-based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum 2019; 49: 43-55
• 12 Heiligenhaus A, Klotsche J, Niewerth M. et al. Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany. Arthritis Res Ther 2020; 22: 81
• 13 Kothari S, Foster CS, Pistilli M. et al. The risk of intraocular pressure elevation in pediatric non-infectious uveitis. Ophthalmology 2015; 122: 1987-2001
• 14 Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005; 32: 362-365
• 15 Heiligenhaus A, Mingels A, Heinz C. et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007; 17: 743-748
• 16 Samson CM, Waheed N, Baltatzis S. et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001; 108: 1134-1139
• 17 Kostik MM, Gaidar EV, Hynnes AY. et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol 2016; 34: 714-718
• 18 Papadopoulou C, Kostik M, Böhm M. et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr 2013; 163: 879-884
• 19 Tappeiner C, Schenck S, Niewerth M. et al. Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care Res 2016; 68: 46-54
• 20 Lerman MA, Burnham JM, Chang PY. et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol 2013; 40: 1394-1403
• 21 Acharya N, Patel S, Homayounfar G. et al. Relapse of juvenile idiopathic arthritis associated uveitis after discontinuation of immunomodulatory therapy. Ocul Immunol Inflamm 2019; 27: 686-692
• 22 Lerman MA, Lewen MD, Kempen JH. et al. Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 2015; 160: 193-200
• 23 Horton S, Jones AP, Guly CM. et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE trial. Am J Ophthalmol 2019; 207: 170-179
• 24 Simonini G, Druce K, Cimaz R. et al. Current evidence of anti-tumor necrosis factor a treatment efficacy in childhood chronic uveitis: a systemic review and meta-analysis approach of individual drugs. Arthritis Care Res 2014; 66: 1073-1084
• 25 Vallet H, Seve P, Biard L. et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol 2016; 68: 1522-1530
• 26 Cordero-Coma M, Calvo-Rio V, Adan A. et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm 2014; 2014: 717598
• 27 Miserocchi E, Modorati G, Pontikaki I. et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 2014; 22: 90-95
• 28 Ramanan AV, Dick AD, Jones AP. et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med 2017; 376: 1637-1646
• 29 Tynjälä P, Lindahl P, Honkanen V. et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007; 66: 548-550
• 30 Saurenmann RK, Levin AV, Feldman BM. et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents. J Pediatr 2006; 149: 833-836
• 31 Scrivo R, Spadaro A, Spinelli FR. et al. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008; 58: 1555-1556
• 32 Calvo-Rio V, Santos-Gomez M, Calvo I. et al. Anti-IL-6R tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-TNF therapy. A multicenter study of 25 patients. Arthritis Rheumatol 2016; 69: 668-675
• 33 Tappeiner C, Mesquida M, Adan A. et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2016; 43: 2183-2188
• 34 Ramanan AV, Dick AD, Guly C. et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol 2020; 2: e135-e141
• 35 Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis – a case report. J Rheumatol 2008; 35: 1897-1898
• 36 Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Arthritis Care Res 2011; 63: 307-310
• 37 Tappeiner C, Miserocchi E, Bodaghi B. et al. Abatacept in the treatment of severe, longstanding and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2015; 42: 706-711
• 38 Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocular Immunol Inflamm 2019; 27: 1232-1234
• 39 Miserocchi E, Giuffre C, Cornalba M. et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol 2020; 39: 847-851
• 40 Heiligenhaus A, Miserocchi E, Heinz C. et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011; 50: 1390-1394
• 41 Miserocchi E, Pontikaki I, Modorati G. et al. Rituximab for uveitis. Ophthalmology 2011; 118: 223-224
• 42 Miserocchi E, Modorati G, Berchicci L. et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 2016; 100: 782-786
• 43 Kalinina Ayuso V, van de Winkel EL, Rothova A. et al. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151: 217-222